Literature DB >> 24039090

Center variation in the use of nonstandardized model for end-stage liver disease exception points.

David S Goldberg1, George Makar, Therese Bittermann, Benjamin French.   

Abstract

The Model for End-Stage Liver Disease (MELD) score is an imperfect prognosticator of waitlist dropout, so transplant centers may apply for exception points to increase a waitlist candidate's priority on the waitlist. Exception applications are categorized as recognized exceptional diagnoses (REDs; eg, hepatocellular carcinoma) and non-REDs (eg, cholangitis). Although prior work has demonstrated regional variation in the use of exceptions, no work has examined the between-center variability. We analyzed all new waitlist candidates from February 27, 2002 to June 3, 2011 to explore variations in the use of non-REDs, for which no strict exception criteria exist. There were 58,641 new waitlist candidates, and 4356 (7.4%) applied for a non-RED exception. The number of applications increased steadily over time, as did the approval rates for such applications: from <50% in 2002 to nearly 75% in 2010. When we adjusted for patient factors, there was significant variability (P < 0.001) in the use of non-RED exceptions in 8 of 11 United Network for Organ Sharing (UNOS) regions and in the approval of these exceptions in 6 of 11 UNOS regions. The variability in the use and approval of non-REDs was clinically significant: waitlist candidates with approved exceptions were significantly more likely to undergo transplantation (68.3% versus 53.4%, P < 0.001) and were less likely to be removed for death or clinical deterioration (10.4% versus 16.2%, P < 0.001). Increased median MELD score at transplantation within a donor service area was the only center factor associated with increased odds of applying for exceptions, while no center factors were associated with having non-RED exceptions approved. Further work is needed to identify other sources of variation to ensure the appropriate and equitable use of non-RED exceptions.
© 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 24039090     DOI: 10.1002/lt.23732

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  Competing risks and the risks of children and adults competing for livers.

Authors:  Paul A MacLennan; Babak J Orandi
Journal:  Am J Transplant       Date:  2020-07-25       Impact factor: 8.086

2.  Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.

Authors:  Yael R Nobel; David S Goldberg
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

3.  Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years: Analysis of the UNOS Database.

Authors:  Noelle H Ebel; Evelyn K Hsu; Kristin Berry; Simon P Horslen; George N Ioannou
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

Review 4.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

5.  Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Authors:  Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncology       Date:  2020-10-07       Impact factor: 2.935

6.  United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.

Authors:  Robert G Gish; Robert J Wong; Gordon Honerkamp-Smith; Ronghui Xu; Robert W Osorio
Journal:  Clin Transplant       Date:  2015-04-16       Impact factor: 2.863

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.